Evidence map›Paper›PMID 40228016›Full record

ArticleThe American journal of case reports2025

Hemoptysis and Anabolic Steroids: A Case Report of Oxandrolone-Induced Bleeding.

Prabhava Bagla, Aparna Das

Abstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Prabhava BaglaDepartment of Hospital Medicine, AdventHealth Orlando, Orlando, FL, USA.ORCID 0000-0002-5328-0638
Aparna DasDepartment of Psychiatry, AdventHealth Orlando, Orlando, FL, USA.ORCID 0000-0002-9173-1858

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Anabolic androgenic steroids (AAS) are associated with multiple adverse effects. They can cause thrombotic as well as hemorrhagic manifestations. Oxandrolone is one such AAS that used to be approved by the FDA for treatment of malnutrition and weight loss following severe burn injury, trauma, HIV-related wasting and neuromuscular disorders. It was previously inappropriately used by athletes for muscle build-up. Recently, the FDA withdrew approval over safety and efficacy concerns. CASE REPORT A 20-year-old otherwise healthy man presented with a 4-day history of early-morning hemoptysis. He had recently used oxandrolone for supplementing muscle growth. Hemoptysis was witnessed by hospital staff. Flexible nasopharyngolaryngoscopy demonstrated easy bleeding without a localized lesion. Hemoptysis progressively declined during hospitalization, and eventually completely resolved. CONCLUSIONS Anabolic androgenic steroids can lead to bleeding manifestations in otherwise healthy patients, which resolve upon cessation of use. A thorough evaluation of all medications, prescribed or otherwise, is particularly important when dealing with unusual presenting symptoms. AAS might not appear on standard medication reconciliation sections in electronic medical records or on basic toxicology screen results. Further research is needed to elucidate factors that can influence bleeding versus thrombotic manifestations.

Indexed as

Anabolic AgentsHemoptysisOxandroloneAnabolic Androgenic SteroidsHumansMaleYoung AdultAnabolic AgentsAnabolic Androgenic SteroidsOxandrolone

Identifiers

PMID40228016
PMCPMC12007561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.